Sept 11 (Reuters) - Cannimed Therapeutics Inc:
* Cannimed Therapeutics Inc. reports financial results for Q3 2017
* Cannimed Therapeutics Inc - for three months ended July 31, 2017, company recorded loss from continuing operations of $1.4 million, or $0.06 per share
* Cannimed Therapeutics-with current, planned cap ex, co is targeting production expansion estimated to reach 17,000 to 21,000 kg within next 24 months
* Q3 sales rose 80 percent to C$4.8 million Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.